Respiratory involvement in antineutrophil cytoplasmic antibody-associated vasculitides: a retrospective study based on POLVAS registry

Biedroń, Grzegorz; Włudarczyk, Anna; Wawrzycka-Adamczyk, Katarzyna; Wójcik, Krzysztof; Musiał, Jacek; Bazan-Socha, Stanisława; Zdrojewski, Zbigniew; Masiak, Anna; Czuszyńska, Zenobia; Majdan, Maria; Jeleniewicz, Radosław; Klinger, Marian; Krajewska, Magdalena; Augustyniak−Bartosik, Hanna; Jakuszko, Katarzyna; Brzosko, Marek; Brzosko, Iwona; Dębska‐Ślizień, Alicja; Storoniak, Hanna; Bułło‐Piontecka, Barbara; Tłustochowicz, Witold; Kur-Zalewska, Joanna; Wisłowska, Małgorzata; Madej, Marta; Hawrot-Kawecka, Anna; Głuszko, Piotr; Kucharz, Eugeniusz J.; Szczeklik, Wojciech

doi:10.55563/clinexprheumatol/tvtyen

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reported previously [ 4 , 5 , 16 ], the prevalence of pulmonary involvement in MPA is high, and ILD is the most common pulmonary manifestation. However, whether there is a pathogenic relationship between MPA and pulmonary involvement remains unclear.…”

Section: Discussionsupporting

confidence: 60%

Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities

Zhang

Ding

et al. 2023

Annals of Medicine

View full text Add to dashboard Cite

Background The association between pulmonary involvement and microscopic polyangiitis (MPA) has been increasingly recognized in recent years. Whether interstitial lung disease (ILD) and bronchiectasis (BE) are disease manifestations of MPA, preexisting comorbidities or important complications remains unclear. The purpose of this study was to determine the clinical characteristics and prognosis of MPA with pulmonary involvement to further guide clinical management. Methods The data for 97 patients with a definitive diagnosis of MPA were retrospectively reviewed. The MPA diagnosis was based on the 2012 revised Chapel Hill Consensus Conference (CHCC) criteria. The baseline clinical information and laboratory parameters were collected and analysed at each patient’s initial diagnosis. Results Forty-seven out of the 97 (48.5%) patients who were diagnosed with MPA presented with pulmonary involvement, including 37 patients with ILD, 12 patients with BE and two patients with diffuse alveolar haemorrhage (DAH). ILD and BE antedated MPA in 56.76% and 75.00% of the patients, respectively. Compared with that in the MPA-BE group, the serum LDH level (222.86 ± 68.19 vs. 171.58 ± 31.43, p = .016) in the MPA-ILD group was significantly higher. In the multivariate Cox analysis, elevated serum creatinine (HR 4.08, confidence interval (CI) 1.38–12.05, p = .011) was an independent risk factor for shorter survival in MPA patients with pulmonary involvement, and treatment with glucocorticoid pulse cyclophosphamide therapy (HR 0.095, 95% CI 0.019–0.47, p = .004) was independently associated with prolonged survival. Among the patients in the MPA-ILD group, acute exacerbations of ILD (HR 4.55 CI 1.16–17.86, p = .029) and elevated serum creatinine (HR 4.95, CI 1.39–17.54, p = .014) were independently associated with a poor prognosis, and treatment with glucocorticoids (HR 0.057, 95% CI 0.012–0.28, p < .001) was independently associated with significant prolongation of survival. Conclusions Patients with MPA have a high prevalence of pulmonary involvement, and ILD is the most common subtype of MPA. ILD and BE can be considered preexisting comorbidities of MPA. Elevated serum creatinine was associated with shorter survival. However, remission induction regimens with glucocorticoids and/or immunosuppressants may improve this outcome.

show abstract

Section: Discussionsupporting

confidence: 60%